Anthrax toxin, comprising of protective antigen (PA), lethal factor (LF) and edema factor (EF) is a major virulent factor of B. anthracis. Protective antigen, PA is the main component of all the vaccines against anthrax. The protective efficacy of PA is greatly increased if small quantities of LF of EF are incorporated into the vaccines. An ideal vaccine against anthrax should contain PA, LF and EF together, but this combination would be toxic. Therefore, the biologically inactive mutant preparations of PA, LF and EF may be used together for better immunoprotection. The present invention describes the method for generation of recombinant vaccine against anthrax, comprising of non-toxic, mutant anthrax toxin proteins. The procedure involves site-directed mutagenesis of the native genes of the toxin proteins, the expression and purification of the mutant proteins and finally characterization of these proteins.

Title
Process for the preparation of non-toxic anthrax vaccine
Application Number
10/497673
Publication Number
20050063986
Application Date
March 20, 2002
Publication Date
March 24, 2005
Inventor
Praveen Kumar
Nidhi Ahuja
Aparna Singh
Vibha Chauhan
Smriti Batra
Pankaj Gupta
Rakesh Bhatnagar
Agent
Ladas & Parry
NY, US
IPC
C12N 15/74
C07K 14/32
C12N 01/21
A61K 39/02
C07H 21/04
C12Q 01/68
View Original Source